Common TitleHBV-23: Heplisav-B versus Engerix-B in Subpopulations Aged 18-70
Official Title A Phase 3, Observer-Blinded, Randomized, Active-Controlled (Engerix-B), Multicenter Trial of the Safety and Immunogenicity of HEPLISAV in Adults 18 to 70 Years of Age
Phase Phase III
ClinicalTrials.gov NCT02117934
Treatments
Heplisav-B
Heplisav-B
Tradename:Heplisav-BOther Names:Hepatitis B Vaccine (Recombinant) Adjuvanted, HepB-CpGClass:Vaccines (HBV)Funding
IndustryDynavax Technologies Corporation